<DOC>
	<DOCNO>NCT00530088</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use drug becomes active expose certain kind light . When drug active , tumor cell kill . Photodynamic therapy use porfimer sodium may effective mouth throat dysplasia cancer mouth throat . PURPOSE : This phase I trial study well photodynamic therapy use porfimer sodium work treat patient recurrent mouth throat dysplasia , recurrent situ cancer mouth throat , stage I cancer mouth throat .</brief_summary>
	<brief_title>Photodynamic Therapy Using Porfimer Sodium Treating Patients With Recurrent Mouth Throat Dysplasia Recurrent In Situ Cancer Stage I Cancer Mouth Throat</brief_title>
	<detailed_description>OBJECTIVES : - To determine response patient recurrent dysplasia , squamous cell carcinoma situ , stage I squamous cell carcinoma oral cavity larynx treat photodynamic therapy use porfimer sodium . - To identify local toxicity treatment patient . OUTLINE : Patients receive porfimer sodium subcutaneously follow photodynamic therapy ( PDT ) comprise laser light deliver single diffuser ( i.e. , broad area dysplasia ) fiberoptic lens fiber . Patients incompletely treat miss site disease may receive another dose laser light day 5 without additional porfimer sodium . Patients multicentric disease may undergo additional PDT least 4-6 week initial treatment . After completion study therapy , patient follow 1-2 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Dihematoporphyrin Ether</mesh_term>
	<mesh_term>Trioxsalen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy confirm oral cavity larynx lesion mildtosevere dysplasia OR situ stage I ( T1 , N0 ) squamous cell carcinoma oral cavity larynx Recurrent disease PATIENT CHARACTERISTICS : ECOG performance status 02 WBC ≥ 4,000/mm^3 Platelet count ≥ 100,000/mm^3 Total bilirubin ≤ 2.0 mg/dL Creatinine ≤ 2.0 mg/dL Alkaline phosphatase ≤ 3 time upper limit normal ( ULN ) SGOT ≤ 3 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must practice effective contraception No porphyria hypersensitivity porphyrin porphyrinlike compound PRIOR CONCURRENT THERAPY : Any type prior therapy allow More 4 week since prior concurrent chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I squamous cell carcinoma larynx</keyword>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage 0 laryngeal cancer</keyword>
	<keyword>stage 0 lip oral cavity cancer</keyword>
</DOC>